Pharmaceutisch Weekblad

, Volume 8, Issue 1, pp 26–28 | Cite as

Quinolones in vitro

  • F. Th. C. Willems
Quinolones in Perspective


The first quinolone compound, nalidixic acid, showed activity against a limited number of Gram-negative micro-organisms. ‘One step’ resistance developed hiin vitro and during treatment. Resistance was not mediated by transfer of R-plasmids, which is a characteristic of all quinolones. Newer quinolones like oxolinic acid, piromidic acid, cinoxacin and pipemidic acid exhibit an extended spectrum of activity against Gram-negative bacteria at lower MIC values. In recent years fluorinated quinolones were introduced like ciprofloxacin, norfloxacin, pefloxacin, ofloxacin, enoxacin and amifloxacin. These compounds exhibitin vitro a broad spectrum of activity against Gram-negative and Gram-positive bacteria at MIC values seventy to four hundred times less than those for nalidixic acid. Thein vitro activity of these compounds has been investigated in a large study of uncomplicated urinary tract infections in general practice (PINISU). No resistance was found. The fluorinated quinolones are very promising antimicrobial agents for a limited number of indications.

Key words

Drug resistance In vitro activity Quinolones Spectrum of activity 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Hovelius B, Mardh P, Bygren P. Urinary tract infections caused byStaphylococcus saprophyticus: recurrences and complications. J Urol 1979;122:645–7.Google Scholar
  2. 2.
    Latham RH, Running GK, Stamm WE. Urinary tract infection in young adult women caused byStaphylococcus saprophyticus. JAMA 1983;250:3063–6.Google Scholar
  3. 3.
    Maskell R. Importance of coagulase-negativeStaphylococci as pathogens in the urinary tract. Lancet 1974;1:1155–8.Google Scholar
  4. 4.
    Ericsson HM, Sherris JC. Antibiotic sensitivity testing. Report of an International Collaborative Study (ICS). Acta Pathol Microbiol Scand 1971;section B(suppl 217).Google Scholar
  5. 5.
    Greenwood D, Osman M, Goodwin J, Cowlishaw WA, Slack R. Norfloxacin: activity against urinary pathogens and factors influencing the emerge of resistance. J Antimicrob Chemother 1984;13:315–23.Google Scholar
  6. 6.
    King A, Shannon K, Philips I. Thein vitro activity of ciprofloxacin compared with that of norfloxacin and nalidixic acid. J Antimicrob Chemother 1984;13:325–31.Google Scholar
  7. 7.
    Moreau N, Badet B, Cerceau C, Le Goffic F.In vitro studies of pefloxacin, a new quinolone related to nalidixic acid. Chemioterapia 1982;1:445–50.Google Scholar
  8. 8.
    Reeves DS, Bywater MJ, Holt HA, White LO.In vitro studies with ciprofloxacin, a new 4-quinolone compound. J Antimicrob Chemother 1984;131:333–46.Google Scholar
  9. 9.
    Thabaut A, Durasoir JL. Comparativein vitro antibacterial activity of pefloxacin (1589 RB), nalidixic acid, pipemidic acid and flumequin. Drugs Exp Clin Res 1983;9:229–34.Google Scholar
  10. 10.
    Barry AL, Jones RN. Cross-resistance among cinoxacin, ciprofloxacin, DJ-6783, enoxacin, nalidixic acid. norfloxacin and oxolinic acid afterin vitro selection of resistant populations. Antimicrob Agents Chemother 1984;23:559–64.Google Scholar

Copyright information

© Royal Dutch Association for Advancement of Pharmacy 1986

Authors and Affiliations

  • F. Th. C. Willems
    • 1
  1. 1.Foundation Medical LaboratoriesBredaThe Netherlands

Personalised recommendations